The insulin pump cartridges, which were shipped by J&J’s Animas unit between November 30, 2010 and January 4, 2011, may leak meaning that the correct dosage is not delivered.
Animas spokeswoman Caroline Pavis told the Wall Street Journal that, as of yesterday, the firm has received 22 reports of adverse events linked to the products.
Pavis added that the affected cartridges, which represent about 5 per cent of the firm’s annual output, a comprised of five batches, four of which were shipped to the US and one sold in France.
The news is another blow for J&J which has recalled hundreds of thousands of different products over the last 18 months as a result of a range of quality issues and manufacturing problems.
And J&J's quality woes may be about to get worse. According to Reuters, the firm’s Cordis unit recently received a US Food and Drug Administration (FDA) warning letter about heart devices made at its in San German, Puerto Rico, facility.
The letter has not yet been posted on the FDA's website and J&J has not yet commented.
Crucell to delist
In other news, J&J has acquired a 98.93 per cent holding in Netherlands-based Crucell, manufacturer of the PER.C6 cell line.
The US healthcare major said that Crucell intends to delist from the Exonext Amsterdam, Swiss Exchange and the NASDAQ
Speaking earlier this year J&J said that the Dutch firm’s strength in vaccine production and manufacturing was the key driver for the deal.